Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Long-acting injectable paliperidone can improve adherence in psychotic patients and reduce relapses and healthcare resource utilization (HRU). This study compares the effectiveness of the three-monthly paliperidone palmitate (PP3M) with the one-monthly formulation (PP1M) and investigates reasons that hinder the use of PP3M in real-world settings.
Methods: The authors conducted a three-phase observational study. For subjects recruited from six psychiatric services in Milan, HRU outcomes of PP3M prescription were evaluated through a 12-month mirror-image design (phase 1) and a comparison of HRU of PP1M-only subjects and PP3M subjects during the year prior to PP3M initiation (phase 2). Lastly, they conducted a survey among physicians concerning reasons for not switching to PP3M (phase 3).
Results: A total of 119 subjects (61 on PP3M and 58 on PP1M) were included. One year after PP3M initiation, outpatients' visits decreased significantly. Comparing PP3M with PP1M subjects, no significant difference was found in HRU. Perception of patient's unstable clinical condition was the main reason for maintaining PP1M (32.8%), followed by the need for monthly monitoring (19.7%).
Conclusion: PP3M initiation was associated with an overall HRU reduction. Subjects switched to PP3M had similar HRU when compared to those who did not, suggesting similar clinical conditions in both groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737175.2023.2263650 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians.
Patient Prefer Adherence
May 2025
Department of Neurology, Santa Lucía University Hospital, Cartagena, Murcia, 30202, Spain.
Background: Patient satisfaction and perceived treatment effectiveness play a critical role in healthcare outcomes and overall well-being. Understanding patient experiences can help identify barriers to adherence and guide improvements in therapy. Previous studies, such as those conducted with PP3M and PP1M, have highlighted the importance of patient satisfaction in optimizing the management of chronic conditions, demonstrating that satisfaction is linked to better adherence and overall treatment success.
View Article and Find Full Text PDFTreatment Persistence of Paliperidone Palmitate 3-Month in Patients With Schizophrenia: A Japan Medical Data Center Claims Database Analysis.
Neuropsychopharmacol Rep
June 2025
Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Aim: To examine treatment persistence rates of paliperidone palmitate 3-month (PP3M) for schizophrenia in Japan because evidence in real-world settings is limited.
Methods: A retrospective population-based cohort study was conducted using the Japan Medical Data Center claims database. The overall cohort comprised schizophrenia patients aged ≥ 18 years, who received paliperidone palmitate 1-month (PP1M) within 180 days before initiating PP3M.
An analysis of the clinical application of paliperidone palmitate injection based on real-world.
Front Pharmacol
March 2025
Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China.
Objective: To analyze the clinical application, adherence and relapse of paliperidone palmitate (PP) injection.
Method: The information of patients treated with PP 1-month (PP1M), patients switching from PP1M to paliperidone palmitate 3-month (PP3M), and the relapse of patients after discharge from 1 January 2021 to 31 December 2023 was retrieved from the electronic medical record system. Descriptive statistics, two-tailed -test and Chi-Squared test are used to process data.
Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y).
Front Psychiatry
March 2025
Department of Neurology, Santa Lucía University Hospital, Cartagena, Murcia, Spain.
Background: LAIs with longer dosing intervals appear to be associated with improved clinical outcomes and added real-world benefits in the management of schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides the longest dosing interval, twice-yearly dosing, among all currently available LAIs. In clinical trials PP6M was found to be non-inferior in preventing relapses in patients with schizophrenia compared to the three monthly formulation (PP3M) though real world data remain limited.
View Article and Find Full Text PDFHealth-Care Utilisation and Costs of Transition from Paliperidone Palmitate 1-Monthly to 3-Monthly Treatment for Schizophrenia: A Real-World, Retrospective, 24-Month Mirror-Image Study.
Neuropsychiatr Dis Treat
October 2024
Department of Environmental and Occupational Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Introduction: Poor adherence to antipsychotics in patients with schizophrenia is a leading cause of relapse and functional deterioration. Long-acting injectable paliperidone may reduce relapse risks, health-care utilisation, and health-care costs in these patients.
Methods: In this 24-month mirror-image study, we compared health-care utilization and costs before and after the initiation of paliperidone palmitate 3-monthly (PP3M) treatment in patients with schizophrenia spectrum disorders.